Wells Fargo Initiates Coverage On Myriad Genetics With Equal-Weight Rating, Announces Price Target of $20
Wells Fargo Initiates Coverage On Myriad Genetics With Equal-Weight Rating, Announces Price Target of $20
富國銀行以同等權重評級啓動對多種遺傳學的報道，宣佈目標股價爲20美元
Wells Fargo analyst Timothy Daley initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight rating and announces Price Target of $20.
富國銀行分析師蒂莫西·戴利以同等權重評級開始對Myriad Genetics（納斯達克股票代碼：MYGN）進行報道，並宣佈目標股價爲20美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。